Literature DB >> 6428245

Use of antigen preparations of the amastigote stage of Trypanosoma cruzi in the serology of Chagas' disease.

F G Araujo, D Guptill.   

Abstract

Antigens derived from the amastigote or the epimastigote stages of Trypanosoma cruzi and prepared by sonication or formalinization were examined and compared in the immunofluorescent antibody (IFA) test and enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to the parasite in sera of infected humans. The results revealed that antigens derived of amastigotes from cell cultures can be used for the detection of antibodies to T. cruzi in both tests. In the IFA test, 46.3% of the sera had higher titers with amastigote antigens, 41.5% had equal titers with antigens from both stages, and 12.2% had higher titers with epimastigote antigens. In the ELISA, 43.9% had higher titers with amastigote antigens, 43.9% had equal titers with antigens of both stages and 12.2% had higher titers with the epimastigote antigens. The differences in titers, however, were not of a magnitude sufficient to indicate a higher sensitivity for the amastigote antigens. The ELISA was performed successfully with formalinized or sonicated organisms of both stages. The use of formalinized parasites introduces a new advantage over previously reported ELISA methods. Formalinized antigens are easier to prepare and can be stored for prolonged periods of time at 4 degrees C. The reason for the higher titers with amastigote antigens was examined by using 125I-labeled antigens to determine the binding of antigens to the plastic solid-phase used in the ELISA and to compare the antigens of each stage that could be immunoprecipitated by antibodies to T. cruzi. The ability of amastigote antigens to bind to the plastic solid phase appeared to be slightly higher than that of epimastigote antigens although the differences were not statistically significant. On the other hand, the amount of antigens in the amastigote preparation immunoprecipitated by antibodies in 6 of 10 sera examined was higher than the amount of antigens in the epimastigote preparation immunoprecipitated by antibodies in the same sera. In two sera the amount was similar, and in the remainder more antigens in the epimastigote antigen preparation were immunoprecipitated. These results are of interest and may suggest clinical implications.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6428245     DOI: 10.4269/ajtmh.1984.33.362

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  10 in total

1.  Development and comparison of enzyme immunoassays for diagnosis of Chagas' disease using fixed forms of Trypanosoma cruzi (Epimastigotes, Amastigotes, and Trypomastigotes) and assessment of antigen stability for the three assays.

Authors:  Mariolga Berrizbietia; Momar Ndao; Marcelo Gottschalk; Alberto Aché; Fabio Vásquez; Sonia Lacouture; Mehudy Medina; Brian J Ward
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

2.  Serological diagnosis of Chagas' disease: a potential confirmatory assay using preserved protein antigens of Trypanosoma cruzi.

Authors:  R P Mendes; S Hoshino-Shimizu; A M Moura da Silva; I Mota; R A Heredia; A O Luquetti; P G Leser
Journal:  J Clin Microbiol       Date:  1997-07       Impact factor: 5.948

3.  Analysis of Trypanosoma cruzi antigens bound by specific antibodies and by antibodies to related trypanosomatids.

Authors:  F G Araujo
Journal:  Infect Immun       Date:  1986-07       Impact factor: 3.441

4.  Immunoglobulin A antibodies to Trypanosoma cruzi antigens in digestive forms of Chagas' disease.

Authors:  K S Primavera; S Hoshino-Shimizu; E S Umezawa; B A Peres; D A Manigot; M E Camargo
Journal:  J Clin Microbiol       Date:  1988-10       Impact factor: 5.948

5.  High resolution of Trypanosoma cruzi amastigote antigen in serodiagnosis of different clinical forms of Chagas' disease.

Authors:  T K Matsumoto; S Hoshino-Shimizu; P M Nakamura; H F Andrade; E S Umezawa
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

6.  Purified excreted-secreted antigens from Trypanosoma cruzi trypomastigotes as tools for diagnosis of Chagas' disease.

Authors:  Mariolga Berrizbeitia; Momar Ndao; José Bubis; Marcelo Gottschalk; Alberto Aché; Sonia Lacouture; Mehudy Medina; Brian J Ward
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

7.  Immunization with Trypanosoma cruzi epimastigote antigens incorporated into iscoms protects against lethal challenge in mice.

Authors:  F G Araujo; B Morein
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

8.  Development of resistance to Trypanosoma cruzi in mice depends on a viable population of L3T4+ (CD4+) T lymphocytes.

Authors:  F G Araujo
Journal:  Infect Immun       Date:  1989-07       Impact factor: 3.441

9.  Circulating Trypanosoma cruzi from the same cloned population show differences in the ability to infect cells and to cause lethal infection in mice.

Authors:  E H de Titto; D Israelski; F G Araujo
Journal:  Experientia       Date:  1987-12-01

10.  Highly discordant serology against Trypanosoma cruzi in central Veracruz, Mexico: role of the antigen used for diagnostic.

Authors:  Daniel Guzmán-Gómez; Aracely López-Monteon; María de la Soledad Lagunes-Castro; Carolina Álvarez-Martínez; Manuel Jesús Hernández-Lutzon; Eric Dumonteil; Angel Ramos-Ligonio
Journal:  Parasit Vectors       Date:  2015-09-17       Impact factor: 3.876

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.